Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million
The funding will accelerate the clinical development of investigational adipose stem cell-derived tissue regeneration products
08-Nov-2022 -
Novadip Biosciences, a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, announced that it has raised an additional EUR 40 million in a Series B equity round and ...
adipose stem cells
bone defects
clinical development
+5